Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 9:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 64 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Transplant Tolerance Clear all
Terminated Phase 2 Interventional

A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)

NCT04803058
View directory record Official record
Conditions
Kidney Transplantation
Interventions
TCD601
Biological
Lead sponsor
ITB-Med LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 6, 2026, 9:58 AM EDT
Not listed Phase 1Phase 2 Interventional

Kidney and Blood Stem Cell Transplantation That Eliminates Requirement for Immunosuppressive Drugs

NCT00319657
View directory record Official record
Conditions
Immune Tolerance
Interventions
Hematopoietic cell transplantation, Total lymphoid irradiation
Biological · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Sep 6, 2026, 9:58 AM EDT
Completed Phase 1 Interventional

Trial of Adoptive Immunotherapy With TRACT to Prevent Rejection in Living Donor Kidney Transplant Recipients

NCT02145325
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Expanded Tregs
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Sep 6, 2026, 9:58 AM EDT
Not listed Phase 1Phase 2 Interventional

Induction of Donor Specific Tolerance in Recipients of Live Donor Kidney Allografts by Donor Stem Cell Infusion

NCT00498160
View directory record Official record
Conditions
Renal Failure
Interventions
Enriched Hematopoietic Stem Cell Infusion
Biological
Lead sponsor
Talaris Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2024
U.S. locations
2
States / cities
Chicago, Illinois • Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 17, 2022 · Synced Sep 6, 2026, 9:58 AM EDT
Completed Phase 2 Interventional

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

NCT00005854
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
cyclophosphamide, cyclosporine, methotrexate, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
4
States / cities
Baltimore, Maryland • Worcester, Massachusetts • Columbia, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2011 · Synced Sep 6, 2026, 9:58 AM EDT
Recruiting No phase listed Observational

Changes in Glucose Tolerance in Patients With Cirrhosis Peri-Liver Transplant

NCT06950788
View directory record Official record
Conditions
Cirrhosis, Liver, Diabetes Mellitus Risk, Transplant; Failure, Liver, Transplant-Related Disorder
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 6, 2026, 9:58 AM EDT
Completed Phase 1 Interventional

Combined Bone Marrow and Kidney Transplant for Multiple Myeloma With Kidney Failure

NCT00062621
View directory record Official record
Conditions
Kidney Failure, Chronic, Multiple Myeloma
Interventions
Combined bone marrow and kidney transplant
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Sep 6, 2026, 9:58 AM EDT
Not yet recruiting Early Phase 1 Interventional

Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation

NCT07358195
View directory record Official record
Conditions
Kidney Failure Chronic, Stem Cell Transplant, Stem Cell Transplant Complications, Tolerance, Hematologic Cancer
Interventions
Venetoclax, Hematopoietic Cell Transplantation Conditioning Regimen, Kidney Transplant, Hematopoietic Cell Transplantation
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 6, 2026, 9:58 AM EDT
Completed Phase 2 Interventional Results available

Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients

NCT01638559
View directory record Official record
Conditions
Liver Transplant Recipients, Liver Transplantation, Immunosuppression
Interventions
Immunosuppression withdrawal
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 18 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
11
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2019 · Synced Sep 6, 2026, 9:58 AM EDT
Terminated Phase 2 Interventional

Induction of Donor Specific Tolerance in Recipients of Living Kidney Allografts by Donor FCRx Infusion

NCT00497926
View directory record Official record
Conditions
Kidney Failure
Interventions
Enriched Hematopoietic Stem Cell Infusion
Biological
Lead sponsor
Talaris Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2023
U.S. locations
2
States / cities
Chicago, Illinois • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Sep 6, 2026, 9:58 AM EDT
Recruiting Phase 1 Interventional

EVR and EPO for Liver Transplant Tolerance

NCT06832189
View directory record Official record
Conditions
Liver Transplant
Interventions
Everolimus, Epoetin alfa
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 6, 2026, 9:58 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Delayed Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-matched Kidney Transplants

NCT05525507
View directory record Official record
Conditions
End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection, Chronic Kidney Diseases
Interventions
Conditioning and Stem cell infusion
Combination Product
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 6, 2026, 9:58 AM EDT
Terminated No phase listed Observational

Detection and Treatment of Endocrine Abnormalities in Childhood Cancer Survivors and Hematopoietic Stem Cell Transplant Recipients

NCT00504218
View directory record Official record
Conditions
Hypopituitarism, Hypogonadism, Thyroid Dysfunction, Bone Diseases, Metabolic
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
2 Years to 24 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2018 · Synced Sep 6, 2026, 9:58 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Immune Tolerance and Alloreactivity in Liver Transplant Recipients on Different Monotherapy Immunosuppressive Agents

NCT01678937
View directory record Official record
Conditions
Liver Transplant Rejection, Immunosuppression
Interventions
Blood Draw - Rapamycin, Blood Draw from Control Subjects, Blood Draw - CyA, Blood Draw - Tacrolimus, Blood Draw - MMF
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Sep 6, 2026, 9:58 AM EDT
Completed Phase 1Phase 2 Interventional

Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies

NCT00777231
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Enriched Hematopoetic Stem Cell Infusion
Biological
Lead sponsor
Talaris Therapeutics Inc.
Industry
Eligibility
Not listed
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
3
States / cities
Louisville, Kentucky • Durham, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced Sep 6, 2026, 9:58 AM EDT
Terminated Phase 1 Interventional

Prospective L-arginine Study

NCT01485757
View directory record Official record
Conditions
Heart Transplant
Interventions
L-arginine
Drug
Lead sponsor
University of Michigan
Other
Eligibility
8 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Sep 6, 2026, 9:58 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD

NCT02525029
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Pregnyl®
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 76 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Sep 6, 2026, 9:58 AM EDT
Terminated Phase 3 Interventional

A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation

NCT03995901
View directory record Official record
Conditions
Transplanted Organ Rejection
Interventions
FCR001
Biological
Lead sponsor
Talaris Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
18
States / cities
Phoenix, Arizona • La Jolla, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Sep 6, 2026, 9:58 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Liver Transplantation With Tregs at UCSF

NCT03654040
View directory record Official record
Conditions
Liver Transplant
Interventions
arTreg, leukapheresis, cyclophosphamide, mesna, everolimus
Biological · Procedure · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Sep 6, 2026, 9:58 AM EDT
Completed Phase 2 Interventional Results available

Belatacept Post Depletional Repopulation to Facilitate Tolerance

NCT00565773
View directory record Official record
Conditions
Organ Transplantation
Interventions
Belatacept, Sirolimus, Alemtuzumab
Drug
Lead sponsor
Allan D Kirk, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Sep 6, 2026, 9:58 AM EDT
Completed Phase 2 Interventional Results available

Combination Drug Therapy Followed by Single Drug Steroid Free Therapy to Prevent Organ Rejection in Kidney Transplantation

NCT00076570
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Sirolimus, Tacrolimus
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2013 · Synced Sep 6, 2026, 9:58 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor

NCT03707262
View directory record Official record
Conditions
Renal Transplant Rejection, Tolerance, Kidney Transplant
Interventions
Donor CD34+ and CD3+ cells
Biological
Lead sponsor
Jeffrey Veale, MD
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 6, 2026, 9:58 AM EDT
Completed Phase 3 Interventional

Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants

NCT03363945
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
MDR-101
Biological
Lead sponsor
Medeor Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
18
States / cities
Loma Linda, California • Los Angeles, California • Stanford, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Sep 6, 2026, 9:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

HLA-Identical Sibling Renal Transplant Tolerance

NCT00619528
View directory record Official record
Conditions
Immunosuppression, Kidney Transplantation, Graft Rejection
Interventions
Infusion of Donor Hematopoietic Stem Cells and Campath-1H
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 6, 2026, 9:58 AM EDT